single increasing intranasal and subcutaneous doses of a potent luteinizing hormone-releasing hormone ( lh-rh ) agonistic analog ( d-ser [ tbu ] 6-des-gly-nh2 ( 10 ) ) lh-rh ethylamide ( buserelin ) were administered on day 2 or 3 of the follicular phase in 59 normal women .
C0023610
lh-rh
C0006456
buserelin